Home › Head and Neck Squamous Cell Carcinoma › Maryland
Head and Neck Squamous Cell Carcinoma clinical trials in Maryland
18 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in Maryland.
Cities in Maryland
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- University of Maryland Greenebaum Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of Maryland School of Medicine, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06385080Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Central Maryland Radiation Oncology in Howard County, Columbia
- UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Sep 22, 2026 · NCT04671667Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- University of Maryland/Greenebaum Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06589804Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Sep 18, 2026 · NCT06161545Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Greater Baltimore Medical Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Research Site, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06535607A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- University of Maryland, Baltimore
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06163534Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Greater Baltimore Medical Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #14, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05176483FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0112, Baltimore
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 17, 2026 · NCT06788990Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Johns Hopkins Hospital /ID# 254056, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04777994A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT06256588DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA11-0, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT06953089A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Maryland, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06064877A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Upper Chesapeake Health, Bel Air
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2025 · NCT06088381A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.